$3.56
11.25% yesterday
Nasdaq, May 20, 10:19 pm CET
ISIN
CA10778Y3023
Symbol
BCTX
Sector
Industry

BriaCell Therapeutics Corp Stock price

$3.56
-0.63 15.04% 1M
-5.47 60.60% 6M
-4.92 57.99% YTD
-18.79 84.07% 1Y
-1.44 28.80% 3Y
-3.44 49.14% 5Y
-68.08 95.03% 10Y
Nasdaq, Closing price Tue, May 20 2025
+0.36 11.25%
ISIN
CA10778Y3023
Symbol
BCTX
Sector
Industry

Key metrics

Market capitalization $20.35m
Enterprise Value $14.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 2.91
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-27.32m
Free Cash Flow (TTM) Free Cash Flow $-21.98m
Cash position $5.01m
EPS (TTM) EPS $-5.00
Short interest 4.21%
Show more

Is BriaCell Therapeutics Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

BriaCell Therapeutics Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a BriaCell Therapeutics Corp forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a BriaCell Therapeutics Corp forecast:

Buy
100%

Financial data from BriaCell Therapeutics Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jan '25
+/-
%
- -
-
100%
- Direct Costs 0.13 0.13
550% 550%
-
-0.13 -0.13
550% 550%
-
- Selling and Administrative Expenses 5.65 5.65
25% 25%
-
- Research and Development Expense 21 21
11% 11%
-
-27 -27
14% 14%
-
- Depreciation and Amortization 0.13 0.13
550% 550%
-
EBIT (Operating Income) EBIT -27 -27
14% 14%
-
Net Profit -12 -12
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about BriaCell Therapeutics Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BriaCell Therapeutics Corp Stock News

Neutral
GlobeNewsWire
about 17 hours ago
Repeated positive recommendation from Data Safety Monitoring Board (“DSMB”) of pivotal Phase 3 study for lead clinical candidate Bria-IMT™ in combination with checkpoint inhibitor Bria-IMT has received Fast Track designation from FDA and patient enrollment has been accelerating in the pivotal Phase 3 study in metastatic breast cancer Successful completion of the pivotal study may lead to a Biol...
Neutral
GlobeNewsWire
21 days ago
Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, including response rates and survival benefits Positive delayed-type hypersensitivity (DTH) (p = 0.001) and a favorable Neutrophil-to-Lymphocyte Ratio (NLR) (p = 0.02) linked to longer progression-free ...
Neutral
GlobeNewsWire
22 days ago
PHILADELPHIA and VANCOUVER, British Columbia, April 28, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced the closing of its previously announced underwritten public offering of 3,066,666 units, including 399,999 ...
More BriaCell Therapeutics Corp News

Company Profile

BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

Head office Canada
CEO William Williams
Employees 18
Founded 2006
Website www.briacell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today